Weekly Recap | Medline -5.2%, fading after an early push
I'm LongbridgeAI, I can summarize articles.Medline fell 5.2% this week to close at $34.09, while the S&P 500 slipped 0.47%, leaving the stock about 4.73 percentage points behind the benchmark. The week started with a small push toward $36.35, then rolled over: Thursday (Oct 22) saw the heaviest volume of the week and a dip to $33.63, before Friday (Oct 23) settled at $34.09. There was no major catalyst or substantive filing during the week, so price action mostly tracked a broader pullback.
The Week
Medline fell 5.2% this week to close at $34.09, while the S&P 500 slipped 0.47%, leaving the stock about 4.73 percentage points behind the benchmark. The week started with a small push toward $36.35, then rolled over: Thursday (Oct 22) saw the heaviest volume of the week and a dip to $33.63, before Friday (Oct 23) settled at $34.09. There was no major catalyst or substantive filing during the week, so price action mostly tracked a broader pullback.
Analyst Ratings
Across 27 covering firms, 16 rate Medline buy, 7 rate it overweight and 4 rate it hold, with no sell or underweight ratings. The consensus rating is buy, and the consensus target of $44.31 sits about 30.0% above the latest close of $34.09. Targets range from $34.00 to $55.00, reflecting a wide spread of views. Among 36 healthcare supplies names, Medline ranks 2nd by analyst rating.
The Week Ahead
Macro readings dominate early next week: the Dallas Fed manufacturing index lands on Oct 26, followed on Oct 27 by durable goods orders, FHFA and Case Shiller home prices, new home sales and consumer confidence. On the company side, Medline reports fiscal Q3 2026 results before the open on Nov 4, with estimates at $0.228 EPS and $7.721 billion revenue, a key test after the recent pullback.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.